Article thumbnail

The Steroid Catabolic Pathway of the Intracellular Pathogen Rhodococcus equi Is Important for Pathogenesis and a Target for Vaccine Development

By R. van der Geize, A. W. F. Grommen, G. I. Hessels, A. A. C. Jacobs and L. Dijkhuizen

Abstract

Rhodococcus equi causes fatal pyogranulomatous pneumonia in foals and immunocompromised animals and humans. Despite its importance, there is currently no effective vaccine against the disease. The actinobacteria R. equi and the human pathogen Mycobacterium tuberculosis are related, and both cause pulmonary diseases. Recently, we have shown that essential steps in the cholesterol catabolic pathway are involved in the pathogenicity of M. tuberculosis. Bioinformatic analysis revealed the presence of a similar cholesterol catabolic gene cluster in R. equi. Orthologs of predicted M. tuberculosis virulence genes located within this cluster, i.e. ipdA (rv3551), ipdB (rv3552), fadA6 and fadE30, were identified in R. equi RE1 and inactivated. The ipdA and ipdB genes of R. equi RE1 appear to constitute the α-subunit and β-subunit, respectively, of a heterodimeric coenzyme A transferase. Mutant strains RE1ΔipdAB and RE1ΔfadE30, but not RE1ΔfadA6, were impaired in growth on the steroid catabolic pathway intermediates 4-androstene-3,17-dione (AD) and 3aα-H-4α(3′-propionic acid)-5α-hydroxy-7aβ-methylhexahydro-1-indanone (5α-hydroxy-methylhexahydro-1-indanone propionate; 5OH-HIP). Interestingly, RE1ΔipdAB and RE1ΔfadE30, but not RE1ΔfadA6, also displayed an attenuated phenotype in a macrophage infection assay. Gene products important for growth on 5OH-HIP, as part of the steroid catabolic pathway, thus appear to act as factors involved in the pathogenicity of R. equi. Challenge experiments showed that RE1ΔipdAB could be safely administered intratracheally to 2 to 5 week-old foals and oral immunization of foals even elicited a substantial protective immunity against a virulent R. equi strain. Our data show that genes involved in steroid catabolism are promising targets for the development of a live-attenuated vaccine against R. equi infections

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3161971
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2010). 3-Ketosteroid 9alpha-hydroxylase is an essential factor in the pathogenesis of Mycobacterium tuberculosis.
  2. (2007). A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages.
  3. (2008). A novel method to generate unmarked gene deletions in the intracellular pathogen Rhodococcus equi using 5-fluorocytosine conditional lethality.
  4. (1987). Antibody response of horses to Rhodococcus equi antigens.
  5. (1995). Apoptosis, oncosis, and necrosis. An overview of cell death.
  6. (2005). Assessment in mice of vapA-DNA vaccination against Rhodococcus equi infection.
  7. (1991). Association between a large plasmid and 15- to 17-kilodalton antigens in virulent Rhodococcus equi.
  8. (1995). Association with HeLa cells by Rhodococcus equi with and without the virulence plasmid.
  9. (2009). Beta-androstenes and resistance to viral and bacterial infections.
  10. (1990). Catabolism of methylperhydroindanedione propionate by Rhodococcus equi: evidence of a MEPHIP-reductase activity.
  11. (2010). Characterization of the role of the pathogenicity island and vapG in the virulence of the intracellular actinomycete pathogen Rhodococcus equi.
  12. (2008). Chimeric vapA/groEL2 DNA vaccines enhance clearance of Rhodococcus equi in aerosol challenged C3H/He mice.
  13. (2006). Cholesterol oxidase (ChoE) is not important in the virulence of Rhodococcus equi.
  14. (2010). Cholesterol utilization in mycobacteria is controlled by two TetR-type transcriptional regulators: kstR and kstR2.
  15. (1997). Clinical manifestations, diagnosis, treatment, and prevention of Rhodococcus equi infections in foals.
  16. (2010). Current understanding of the equine immune response to Rhodococcus equi.A n immunological review of R. equi pneumonia.
  17. (2003). Deletion of vapA encoding Virulence Associated Protein A attenuates the intracellular actinomycete Rhodococcus equi.
  18. (2000). DNA sequence and comparison of virulence plasmids from Rhodococcus equi ATCC33701 and 103.
  19. (1976). Establishment and characterization of a human histiocytic lymphoma cell line (U937).
  20. (2002). Evaluation of a commercially available hyperimmune plasma product for prevention of naturally acquired pneumonia caused by Rhodococcus equi in foals.
  21. (2008). Evolution of the Rhodococcus equi vap pathogenicity island seen through comparison of host-associated vapA and vapB virulence plasmids.
  22. (1995). Failure of hyperimmune plasma to prevent pneumonia caused by Rhodococcus equi in foals.
  23. (2005). Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages.
  24. (2009). Haas A
  25. (2001). Hartke A
  26. (1992). Hexahydroindanone derivatives of steroids formed by a Rhodococcus equi.
  27. (2005). Identification and characterization of a regulatory sequence recognized by Mycobacterium tuberculosis persistence regulator MprA.
  28. (2001). Identification and mutagenesis by allelic exchange of choE,e n c o d i n ga cholesterol oxidase from the intracellular pathogen Rhodococcus equi.
  29. (2005). Identification of 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oic acid, 4-hydroxy-2-oxohexanoic acid, and 2-hydroxyhexa-2,4-dienoic acid and related enzymes involved in testosterone degradation in Comamonas testosteroni TA441.
  30. (1997). Immunity to Rhodococcus equi.
  31. (2007). Immunization by intrabronchial administration to 1-week-old foals of an unmarked double gene disruption strain of Rhodococcus equi strain 103 +.
  32. (2005). Isocitrate lyase activity is required for virulence of the intracellular pathogen Rhodococcus equi.
  33. (2000). Linear mixed models for longitudinal data. New York: Springer-Verlag. Role Steroid Catabolism
  34. (1967). Mechanisms of steroid oxidation by microorganisms. XII. Metabolism of hexahydroindanpropionic acid derivatives.
  35. (2001). Metacleavage enzyme tesB is necessary for testosterone degradation
  36. (2002). Molecular and functional characterization of kshA and kshB, encoding two components of 3-ketosteroid 9a-hydroxylase, a class IA monooxygenase, in Rhodococcus erythropolis strain SQ1.
  37. (2007). Mutation and virulence assessment of chromosomal genes of Rhodococcus equi 103.
  38. (2008). Mycobacterial persistence requires the utilization of host cholesterol.
  39. (2004). Necrotic death of Rhodococcus equi-infected macrophages is regulated by virulence-associated plasmids.
  40. (2007). Oral administration of a live attenuated Salmonella vaccine strain expressing the VapA protein induces protection against infection by Rhodococcus equi.
  41. (1997). Pathogenesis and virulence of Rhodococcus equi.V e t
  42. (2003). Phenotypic mutants of the intracellular actinomycete Rhodococcus equi created by in vivo Himar1 transposon mutagenesis.
  43. (1991). Protection against naturally acquired Rhodococcus equi pneumonia in foals by administration of hyperimmune plasma.
  44. (1999). Restriction fragment length polymorphisms of virulence plasmids in Rhodococcus equi.
  45. (1989). Rhodococcus equi foal pneumonia: protective effects of immune plasma in experimentally infected foals.
  46. (2010). Rhodococcus equi infection.
  47. (2001). Rhodococcus equi infections in immunocompetent hosts: case report and review.
  48. (1991). Rhodococcus equi plasmids: isolation and partial characterization.
  49. (2009). Rhodococcus equi pulmonarycentral nervous system syndrome: brain abscess in a patient on high-dose steroids—a case report and review of the literature.
  50. (2009). Rhodococcus equi virulence-associated protein A is required for diversion of phagosome biogenesis but not for cytotoxicity.
  51. (1991). Rhodococcus equi: an animal and human pathogen.
  52. (1996). Rhodococcus equi: an emerging opportunistic pathogen.
  53. (2002). Rhodococcus equi: an emerging pathogen.
  54. (2004). Rhodococcus equi.
  55. (1999). Role of the 85-kilobase plasmid and plasmid-encoded virulence-associated protein A in intracellular survivaland virulence ofRhodococcus equi.
  56. (2008). Safety and immunogenicity of a live-attenuated auxotrophic candidate vaccine against the intracellular pathogen Rhodococcus equi.
  57. (1993). Some new intermediates in microbial side chain degradation of b-sitosterol.
  58. (2009). Studies of a ring-cleaving dioxygenase illuminate the role of cholesterol metabolism in the pathogenesis of Mycobacterium tuberculosis.
  59. (1994). Survival and replication of Rhodococcus equi in macrophages.
  60. (2008). The actinobacterial mce4 locus encodes a steroid transporter.
  61. (2010). The genome of a pathogenic Rhodococcus: cooptive virulence underpinned by key gene acquisitions.
  62. (2010). The Pfam protein families database.
  63. (2011). The sensor kinase MprB is required for Rhodococcus equi virulence. Vet Microbiol In press.
  64. (1957). The thiobacilli.
  65. (2010). Vaccination of mice with salmonella expressing VapA: mucosal and systemic Th1 responses provideprotectionagainstRhodococcusequiinfection.
  66. (2005). Virulence-associated protein-specific serum immunoglobulin G-isotype expression in young foals protected against Rhodococcus equi pneumonia by oral immunization with virulent R.